HONG KONG, November 16, 2026
Akeso, Inc. (HKEX: 9926.HK) has announced that China’s National Medical Products Administration (NMPA) has accepted its supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC). The application has also received Priority Review designation, marking an important regulatory milestone for the investigational combination therapy. This development represents the fourth marketing application submitted for ivonescimab in China and the first expansion of its clinical development programme into gastrointestinal cancers beyond its established lung cancer indications. The regulatory progress follows positive findings from the pivotal Phase III HARMONi-GI1 clinical trial, which demonstrated statistically significant improvements in overall survival compared with an established immunotherapy-based treatment regimen.
Phase III HARMONi-GI1 Trial Demonstrates Survival Benefits
The sNDA is supported by results from the randomized, double-blind, multicenter Phase III HARMONi-GI1 study (AK112-309), which evaluated ivonescimab combined with chemotherapy against durvalumab combined with chemotherapy in patients receiving first-line treatment for locally advanced or metastatic biliary tract cancer. At a prespecified interim analysis, the study achieved its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement. The trial also met its key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR). The reported median overall survival was 14.9 months with ivonescimab plus chemotherapy compared with 12.1 months with durvalumab plus chemotherapy (HR 0.75; P=0.0031). Median progression-free survival reached 8.4 months versus 5.8 months, respectively (HR 0.61; P<0.0001). The objective response rate was 53.8% in the ivonescimab group compared with 32.5% in the durvalumab group. These findings highlight the potential of the combination therapy to improve treatment outcomes in patients with advanced biliary tract cancer.
Ivonescimab Advances Dual-Targeted Immunotherapy Development
Ivonescimab (AK112) is an investigational bispecific antibody designed to simultaneously target programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). By combining immune checkpoint inhibition with VEGF pathway targeting, the therapy is designed to address two important biological mechanisms involved in tumour growth, immune evasion and tumour angiogenesis. Its combination with chemotherapy represents an investigational approach to improving cancer treatment outcomes by integrating targeted immunotherapy with conventional anticancer treatment. The HARMONi-GI1 findings were presented as a Late-Breaking Abstract during an oral presentation at the ESMO Presidential Symposium in October 2026. According to Akeso, the study represents the first Phase III trial in biliary tract cancer to demonstrate a statistically significant overall survival benefit against a PD-L1 inhibitor plus chemotherapy regimen. The results provide important clinical evidence supporting the continued development of dual-targeted antibody therapies in gastrointestinal oncology.
Global Phase III Development and Regulatory Expansion
Akeso is continuing to expand the global clinical development programme for ivonescimab in biliary tract cancer through the EA2251 Phase II/III registrational study, conducted in collaboration with Summit Therapeutics and the ECOG-ACRIN Cancer Research Group. The international study will evaluate ivonescimab combined with chemotherapy against pembrolizumab or durvalumab combined with chemotherapy in patients receiving first-line treatment for advanced biliary tract cancer. EA2251 represents the seventh international registrational clinical trial involving ivonescimab. The latest NMPA application acceptance strengthens the regulatory development pathway for the therapy in China while additional international clinical research evaluates its potential across different patient populations and treatment settings.
Source: Akeso press release


